黏膜组织中的抗逆转录病毒药理学。
Antiretroviral pharmacology in mucosal tissues.
机构信息
Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599-7569, USA.
出版信息
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2(0 2):S240-7. doi: 10.1097/QAI.0b013e3182986ff8.
Abstract
Strategies to prevent HIV infection using preexposure prophylaxis are required to curtail the HIV pandemic. The mucosal tissues of the genital and rectal tracts play a critical role in HIV acquisition, but antiretroviral (ARV) disposition and correlates of efficacy within these tissues are not well understood. Preclinical and clinical strategies to describe ARV pharmacokinetic-pharmacodynamic relationships within mucosal tissues are currently being investigated. In this review, we summarize the physicochemical and biologic factors influencing ARV tissue exposure. Furthermore, we discuss the necessary steps to generate relevant pharmacokinetic-pharmacodynamic data and the challenges associated with this process. Finally, we suggest how preclinical and clinical data might be practically translated into optimal preexposure prophylaxis dosing strategies for clinical trials testing using mathematical modeling and simulation.
摘要
需要使用暴露前预防策略来预防 HIV 感染，以遏制 HIV 大流行。生殖器和直肠黏膜组织在 HIV 感染中起着关键作用，但这些组织中抗逆转录病毒 (ARV) 的处置和疗效相关因素尚不清楚。目前正在研究描述 ARV 在黏膜组织中药代动力学-药效学关系的临床前和临床策略。在这篇综述中，我们总结了影响 ARV 组织暴露的理化和生物学因素。此外，我们还讨论了生成相关药代动力学-药效学数据的必要步骤，以及与该过程相关的挑战。最后，我们建议如何通过数学建模和模拟，将临床前和临床数据实际转化为最佳的暴露前预防给药策略，用于临床试验测试。
相似文献
1
Antiretroviral pharmacology in mucosal tissues.黏膜组织中的抗逆转录病毒药理学。
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2(0 2):S240-7. doi: 10.1097/QAI.0b013e3182986ff8.
2
Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.抗逆转录病毒药物在生殖分泌物及HIV传播解剖部位的药代动力学：对HIV预防的意义
Clin Pharmacokinet. 2014 Jul;53(7):611-24. doi: 10.1007/s40262-014-0148-z.
3
Pharmacokinetics of antiretrovirals in mucosal tissue.抗逆转录病毒药物在黏膜组织中的药代动力学。
Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):893-905. doi: 10.1517/17425255.2015.1027682. Epub 2015 Mar 22.
4
Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention.六种药物转运体在阴道、宫颈和结直肠组织中的表达：对HIV预防中药物处置的影响。
J Clin Pharmacol. 2014 May;54(5):574-83. doi: 10.1002/jcph.248. Epub 2014 Jan 2.
5
Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis.基于马拉维若的方案作为 HIV 暴露前预防的疗效预测的转化方法。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01729-19.
6
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.一项评估 1%替诺福韦凝胶应用后女性生殖道分泌物和可溶性黏膜免疫中抗 HIV 活性的随机试验。
PLoS One. 2011 Jan 25;6(1):e16475. doi: 10.1371/journal.pone.0016475.
7
Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.达匹韦林与马拉维若单药及联合局部用凝胶预防HIV-1的药效学活性
Pharm Res. 2015 Nov;32(11):3768-81. doi: 10.1007/s11095-015-1738-7. Epub 2015 Jun 16.
8
HIV prevention by oral preexposure prophylaxis.口腔暴露前预防（PrEP）进行艾滋病预防。
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a007419. doi: 10.1101/cshperspect.a007419.
9
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.HIV 暴露前预防：在人源化小鼠模型中 RT 抑制剂替诺福韦和进入抑制剂马拉维若的粘膜组织药物分布。
Virology. 2014 Sep;464-465:253-263. doi: 10.1016/j.virol.2014.07.008. Epub 2014 Aug 7.
10
Critical need for appropriate mucosal sample collection to determine relational animal pharmacokinetic-pharmacodynamic models in HIV prevention.迫切需要采集合适的黏膜样本，以确定HIV预防中相关动物的药代动力学-药效学模型。
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1398-400. doi: 10.1089/AID.2013.0142. Epub 2013 Aug 30.
引用本文的文献
1
Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.阴道药物微生物组学调节持续性和复发性细菌性阴道病的风险。
NPJ Biofilms Microbiomes. 2025 Jul 1;11(1):115. doi: 10.1038/s41522-025-00748-0.
2
The role of pharmacomicrobiomics in HIV prevention, treatment, and women's health.药物微生物组学在艾滋病病毒预防、治疗及女性健康中的作用。
Microbiome. 2024 Dec 3;12(1):254. doi: 10.1186/s40168-024-01953-3.
3
Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals.来那卡帕韦：在抗逆转录病毒药物新时代的长期博弈
Clin Pharmacol Ther. 2025 Feb;117(2):353-367. doi: 10.1002/cpt.3447. Epub 2024 Sep 25.
4
Pharmacokinetics, the Immunological Impact, and the Effect on HIV Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis.马拉维若、雷特格韦和洛匹那韦在男男性行为人群中应用暴露后预防时的药代动力学、免疫影响和对 HIV 感染性的影响。
AIDS Res Hum Retroviruses. 2023 May;39(5):211-221. doi: 10.1089/AID.2021.0232. Epub 2023 Feb 15.
5
HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity.HIV 暴露前预防与性传播感染：交叉与机遇。
Nat Rev Urol. 2022 Jan;19(1):7-15. doi: 10.1038/s41585-021-00527-4. Epub 2021 Oct 25.
6
Irreversible depletion of intestinal CD4+ T cells is associated with T cell activation during chronic HIV infection.慢性 HIV 感染期间，肠道 CD4+ T 细胞的不可逆转耗竭与 T 细胞激活有关。
JCI Insight. 2021 Nov 22;6(22):e146162. doi: 10.1172/jci.insight.146162.
7
Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester.孕晚期母体淋巴细胞和胎儿血浆中抗逆转录病毒药物暴露的机制建模
Front Pediatr. 2021 Sep 20;9:734122. doi: 10.3389/fped.2021.734122. eCollection 2021.
8
Dual Antiretroviral Therapy-All Quiet Beneath the Surface?双抗逆转录病毒疗法——表面之下风平浪静？
Front Immunol. 2021 Feb 12;12:637910. doi: 10.3389/fimmu.2021.637910. eCollection 2021.
9
Pharmacology of HIV Cure: Site of Action.HIV 治愈的药理学：作用部位。
Clin Pharmacol Ther. 2021 Apr;109(4):841-855. doi: 10.1002/cpt.2187. Epub 2021 Mar 5.
10
Human Immunodeficiency Virus Persistence in the Spleen: Opportunities for Pharmacologic Intervention.人类免疫缺陷病毒在脾脏中的持续存在：药物干预的机会。
AIDS Res Hum Retroviruses. 2021 Oct;37(10):725-735. doi: 10.1089/AID.2020.0266. Epub 2021 Feb 22.
本文引用的文献
1
Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions.人类肠道转运体数据库：药物摄取、外排和相互作用的定量构效关系建模和虚拟特征分析。
Pharm Res. 2013 Apr;30(4):996-1007. doi: 10.1007/s11095-012-0935-x. Epub 2012 Dec 27.
2
Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies.坚持使用抗逆转录病毒药物进行HIV暴露前预防：从试验和治疗研究中吸取的经验教训。
Am J Prev Med. 2013 Jan;44(1 Suppl 2):S91-8. doi: 10.1016/j.amepre.2012.09.047.
3
Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand.泰国清迈iPrEx研究中男男性行为者的一项HIV预防研究里药物依从性的促进因素和障碍
AIDS Care. 2013 Aug;25(8):961-7. doi: 10.1080/09540121.2012.748871. Epub 2012 Dec 19.
4
Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.利用人体黏膜组织研究 HIV-1 发病机制和评估 HIV-1 预防方法。
Curr HIV/AIDS Rep. 2013 Mar;10(1):12-20. doi: 10.1007/s11904-012-0148-2.
5
New generation humanized mice for virus research: comparative aspects and future prospects.新一代用于病毒研究的人源化小鼠：比较方面和未来前景。
Virology. 2013 Jan 5;435(1):14-28. doi: 10.1016/j.virol.2012.10.007.
6
Direct imaging of single cells and tissue at sub-cellular spatial resolution using transmission geometry MALDI MS.利用透射几何 MALDI MS 对单细胞和组织进行亚细胞空间分辨率的直接成像。
J Mass Spectrom. 2012 Nov;47(11):1473-81. doi: 10.1002/jms.3108.
7
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?血液细胞中的替诺福韦二磷酸和恩曲他滨三磷酸浓度与分离的外周血单个核细胞比较：一种新的抗逆转录病毒药物依从性衡量方法？
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):260-6. doi: 10.1097/QAI.0b013e3182794723.
8
Next-generation oral preexposure prophylaxis: beyond tenofovir.下一代口服暴露前预防药物：不止替诺福韦。
Curr Opin HIV AIDS. 2012 Nov;7(6):600-6. doi: 10.1097/COH.0b013e328358b9ce.
9
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.用于黏膜 HIV 预防的 90 天替诺福韦储库阴道环。
Antimicrob Agents Chemother. 2012 Dec;56(12):6272-83. doi: 10.1128/AAC.01431-12. Epub 2012 Sep 24.
10
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.接受暴露前预防（PrEP）的男男性行为者的恩曲他滨替诺福韦浓度与预防效果。
Sci Transl Med. 2012 Sep 12;4(151):151ra125. doi: 10.1126/scitranslmed.3004006.
Zotero 插件